'Exciting breakthrough': COVID-19 drug trial to take place in Edmonton
Trials for a Canadian-developed COVID-19 treatment are set to begin at the University of Alberta.
The study will evaluate the safety and efficacy of the drug Apabetalone as a potential oral medication to help prevent severe infection from COVID-19.
“It’s a pretty exciting breakthrough,” Donald McCaffrey, the president and CEO of Resverlogix, said.
The clinical program will test epigenetics on COVID-19 patients, including those who were sick with a variant strain.
“The genetics is the hardware, the epigenetics is the software. The science of learning to turn on or off various genes,” McCaffrey explained.
The drug has been in development for more than 20 years and when COVID-19 emerged, a group of universities began studying drugs already in production that could be repurposed to help fight COVID-19. Apabetalone ended up being “number two on the list,” according to McCaffrey.
“We do have a huge lead on the world in knowledge on this (protein) and how to remove it.”
The drug is an oral pill taken once in the morning and once at night. A total of 100 patients are expected to be enrolled over the coming week to take part in the trial at various sites in Canada and Brazil.
“By removing the bromodomain (BD2) and shutting down the ACE2 receptors, you’re greatly inhibiting the virus’s ability to reproduce,” McCaffrey shared.
'WE DO NOT CHANGE THE HUMAN DNA'
The average COVID-19 hospital stay right now is 11.9 days, McCaffrey told CTV News Edmonton. That stay increases up to 23 days if the patient has cardiovascular issues. He said the cost can range from $26,000 to $52,000 per patient receiving care.
“The goal is to show that we can remove the long hospital stays.”
McCaffrey said because of Apabetalone’s unique epigenetic mechanism, it has the ability to stop disease progression by regulating the “expression” of disease and inflammation-causing genes.
“We do not change the human DNA; it remains identical,” he said. “But, we do turn the genes on or off, and that has a huge therapeutic benefit for our patients.”
In addition to reducing the duration of the disease, the hope is that the drug will also potentially be able to protect those infected from the long-term effects of long-COVID.
'IT WILL BE EFFECTIVE'
Apabetalone would cost about $7 per pill and should be taken for two to three weeks, McCaffrey said.
If the trials are successful, the team's next step would be to apply for an emergency management application in Canada in June, and then in the U.S. about six months later, McCaffrey explained.
“The vaccine is the most important thing at the moment,” Dr. Noel Gibney, professor emeritus, critical care medicine at the U of A, added. “But, we know that even with vaccination, people with critically poor immune systems are still at risk. So, it really is important that we have other therapies.”
With years of data backing the science, efficacy and safety of the drug, McCaffrey is confident it could help “manage the real problem,” which he says is the “bottleneck” in hospitals.
“No matter what Greek alphabet we get hit with next, it will be effective against all future variants.”
With files from CTV News Edmonton’s Carlyle Fiset
CTVNews.ca Top Stories
B.C. tenants evicted for landlord's use after refusing large rent increase to take over neighbouring suite
Ashley Dickey and her mother rented part of the same Coquitlam duplex in three different decades under three different landlords.
Mountain guide dies after falling into a crevasse in Banff National Park
A man who fell into a crevasse while leading a backcountry ski group deep in the Canadian Rockies has died.
Expert warns of food consumption habits amid rising prices
A new survey by Dalhousie University's Agri-Food Analytics Lab asked Canadians about their food consumption habits amid rising prices.
MPP Sarah Jama asked to leave Ontario legislature for wearing keffiyeh
MPP Sarah Jama was asked to leave the Legislative Assembly of Ontario by House Speaker Ted Arnott on Thursday for wearing a keffiyeh, a garment which has been banned at Queen’s Park.
Charlie Woods, son of Tiger, shoots 81 in U.S. Open qualifier
Charlie Woods failed to advance in a U.S. Open local qualifying event Thursday, shooting a 9-over 81 at Legacy Golf & Tennis Club.
Ex-tabloid publisher testifies he scooped up possibly damaging tales to shield his old friend Trump
As Donald Trump was running for president in 2016, his old friend at the National Enquirer was scooping up potentially damaging stories about the candidate and paying out tens of thousands of dollars to keep them from the public eye.
Here's why provinces aren't following Saskatchewan's lead on the carbon tax home heating fight
After Prime Minister Justin Trudeau said the federal government would still send Canada Carbon Rebate cheques to Saskatchewan residents, despite Saskatchewan Premier Scott Moe's decision to stop collecting the carbon tax on natural gas or home heating, questions were raised about whether other provinces would follow suit. CTV News reached out across the country and here's what we found out.
Montreal actress calls Weinstein ruling 'discouraging' but not surprising
A Montreal actress, who has previously detailed incidents she had with disgraced Hollywood producer Harvey Weinstein, says a New York Court of Appeals decision overturning his 2020 rape conviction is 'discouraging' but not surprising.
Caleb Williams, Jayden Daniels and Drake Maye make it four NFL drafts with quarterbacks going 1-3
Caleb Williams is heading to the Windy City, aiming to become the franchise quarterback Chicago has sought for decades.